DUBLIN, Nov 28, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Lung Cancer Therapeutics Market 2016-2020" report to their offering.
The report forecasts the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact on the market. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, nanotechnology approach could radically lower this requirement, allowing much earlier diagnosis or treatment regimes.
According to the report, the market has been witnessing an increased demand for immune-based therapies such as checkpoint inhibitors. There are various types of checkpoint inhibitors that target different checkpoints on immune cells. These treatments work by allowing to mount a stronger and effective attack against lung cancer. The traditional chemotherapy approach involves the destruction of cancerous cells as well as nearby benign cells. This will create a lot of side effects and affects the patient compliance.
Further, the report states that the growing popularity of alternative therapeutics are expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking for alternative therapeutics. The increased demand for these therapies is also due to the high cost of lung cancer therapeutics. Some of the alternative therapeutics include mind and body medicines, biology-based practices, energy work, and whole medical systems.
- F. Hofmann-La Roche
- Eli Lilly
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Disease overview
Part 06: Pipeline analysis
Part 07: Market landscape
Part 08: Market segmentation by disease type
Part 09: Market segmentation by type of molecule
Part 10: Geographical segmentation
Part 11: Market drivers
Part 12: Impact of drivers
Part 13: Market challenges
Part 14: Impact of drivers and challenges
Part 15: Market trends
Part 16: Vendor landscape
Part 17: Key vendor analysis
Part 18: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/hb5x9k/global_lung
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-lung-cancer-therapeutics-market-to-reach-11-billion-by-2020---key-vendors-are-eli-lilly-astrazeneca--pfizer-300368842.html
SOURCE Research and Markets